又一家国内药企布局ADC(抗体偶联药物)赛道。 1月13日,三生制药(1530.HK,股价5.76港元,市值137.99亿港元)发布公告,称附属公司沈阳三生制药有限责任公司(简称“沈阳三生”)及其附属公司与映恩生物科技(上海)有限公司(简称“映恩生物”)就HER2 ADC药物DB-1303达成合作协议。 协议约定,沈阳三生将获得映恩生物开发的HER2 ADC(抗体药物偶联物)药物DB-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.